SAN DIEGO--(BUSINESS WIRE)--Aug. 7, 2018--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), (“Tandem”) a
medical device company and manufacturer of the only touchscreen insulin
pumps available in the United States, today announced the closing of its
previously announced underwritten public offering of 3,508,770 shares of
common stock at a price to the public of $28.50 per share. In addition,
the underwriters fully exercised an option to purchase 526,315
additional shares of common stock at the public offering price. All of
the shares in the offering were offered by Tandem, with gross proceeds
to Tandem of approximately $115 million.
Oppenheimer & Co. Inc. acted as the sole book‐running manager for the
offering. Robert W. Baird & Co. Incorporated acted as a co-manager in
connection with the offering.
A shelf registration statement on Form S-3 relating to these securities
was filed by Tandem with the Securities and Exchange Commission and
declared effective on May 9, 2018. A copy of the final prospectus
supplement and accompanying prospectus relating to and describing the
terms of the offering may be obtained from: Oppenheimer & Co. Inc.
Attention: Syndicate Prospectus Department, 85 Broad St., 26th
Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any
such state or jurisdiction.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. Tandem takes an innovative, user-centric approach to the
design, development and commercialization of products for people with
diabetes who use insulin. Tandem manufactures and sells the t:slim X2™
Insulin Pump with Basal-IQ™ technology. The t:slim X2 Pump is capable of
remote feature updates using a personal computer, and is the first
insulin pump designated as compatible with integrated continuous glucose
monitoring (iCGM) devices. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark, and t:slim X2 and
Basal-IQ are trademarks of Tandem Diabetes Care, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180807005852/en/
Source: Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc.
Media Contact:
Steve
Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investor
Contact:
Susan Morrison, 858-366-6900 x7005
smorrison@tandemdiabetes.com
